



Financial Tear Sheet

Corporate Profile

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

Investor Hotline: 877-5676-CRL

Stock Quote

CRL (COMMON)	
Exchange	NYSE (US Dollar)
Price	\$92.57
Change (%)	▲ 0.87 (0.95%)
Volume	90,015
52 Week Low	\$67.20
Market Cap	\$4,409,976,203
Rolling EPS	3.41
PE Ratio	27.1466
Shares Outstanding	47,639,367
Data as of 05/25/17 12:58 p.m. ET	

Stock Chart



Recent News Releases

05/16/17

Charles River Laboratories Announces Updates to Oncology Business

05/10/17

Charles River Laboratories Announces First-Quarter 2017 Results from Continuing Operations

04/12/17

Charles River Laboratories Schedules First-Quarter 2017 Earnings Release and Conference Call

Upcoming Events

There are currently no events scheduled.

SEC Filings

FILING DATE	FORM
05/16/17	4
05/16/17	4
05/16/17	4
05/16/17	4

Primary IR Contact

Investor Relations
Charles River Laboratories International, Inc.
Phone: 781.222.6000
E-mail: askcharlesriver@crl.com
or askcharlesriver@crl.com

Management Team

James C. Foster	Chairman, President & Chief Executive Officer	Colin Dunn, Ph.D.	Corporate Senior Vice President, Global Research Models & Services
William D. Barbo	Corporate Executive Vice President & Chief Commercial Officer	William H. Eagan	Corporate Senior Vice President and Treasurer
David P. Johst	Corporate Executive Vice President, Human Resources, General Counsel & Chief Administrative Officer	Birgit Girshick	Corporate Senior Vice President, Global Discovery Services
Davide Molho, D.V.M.	Corporate Executive Vice President & President, Global Research Models & Services, Safety Assessment and Biologics	Geoffrey C. Goldsmith	Corporate Senior Vice President, Global Operations Optimization
David R. Smith	Corporate Executive Vice President, Chief Financial Officer & Chief Accounting Officer	John C. Ho, M.D.	Corporate Senior Vice President, Corporate Strategy and Chief Strategy Officer
Brian Bathgate, Ph.D.	Corporate Senior Vice President, European Safety Assessment	Foster T. Jordan	Corporate Senior Vice President, Microbial Solutions
Shanna L. Cotti-Osmanski	Corporate Senior Vice President, Information Technology & Chief Information Officer	Joseph W. LaPlume	Corporate Senior Vice President, Corporate Development

Board of Directors

James C. Foster	Chairman, President & Chief Executive Officer
Robert J. Bertolini	Former President & Chief Financial Officer, Bausch & Lomb Incorporated
Stephen D. Chubb	Former Chairman & Chief Executive Officer, Matritech, Inc.
Deborah T. Kochevar, D.V.M., Ph.D., D.A.C.V.P.	Dean, Cummings School of Veterinary Medicine at Tufts University
George E. Massaro	Vice Chairman, Huron Consulting Group, Inc.
George M. Milne, Jr., Ph.D.	Retired Executive Vice President of Global Research and Development, & President of Central Research, Pfizer Inc.
C. Richard Reese	Former Chairman & Chief Executive Officer, Iron Mountain Incorporated
Craig B. Thompson, M.D.	President & Chief Executive Officer, Memorial Sloan-Kettering Cancer Center
Richard F. Wallman	Former Senior Vice President & Chief Financial Officer, Honeywell International, Inc.

Powered By **EDGAR** Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed